Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options

Thumbnail
View/Open
Use this link to cite
http://hdl.handle.net/2183/32966
Creative Commons Attribution 3.0 International License (CC-BY 3.0)
Except where otherwise noted, this item's license is described as Creative Commons Attribution 3.0 International License (CC-BY 3.0)
Collections
Metadata
Show full item record
Title
Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options
Author(s)
Date
2010-01-12
Citation
Isidro ML, Cordido F. Approved and off-label uses of obesity medications, and potential new pharmacologic treatment options. Pharmaceuticals (Basel). 2010 Jan 12;3(1):125-145.
Abstract
[Abstract] Available anti-obesity pharmacotherapy options remain very limited and development of more effective drugs has become a priority. The potential strategies to achieve weight loss are to reduce energy intake by stimulating anorexigenic signals or by blocking orexigenic signals, and to increase energy expenditure. This review will focus on approved obesity medications, as well as potential new pharmacologic treatment options.
Keywords
Drug treatment
Ghrelin
Leptin
Obesity
Orlistat
Sibutramine
Rimonabant
 
Description
Review
Editor version
Rights
Creative Commons Attribution 3.0 International License (CC-BY 3.0)
ISSN
1424-8247